Regulatory dispatches
FDA compounding policy & the PCAC tracker.
Coverage of FDA compounding policy, the Pharmacy Compounding Advisory Committee, and peptide-related regulatory developments. Every dispatch links back to primary sources.
- 2026-05-04 Research-only peptides: what the documented evidence actually shows →
- 2026-05-03 503A vs 503B: how peptides get compounded in the US →
- 2026-05-03 BPC-157: how it got to PCAC →
- 2026-05-03 DEA scheduling vs FDA approval: what's the difference for peptides →
- 2026-05-03 Dihexa acetate: how it got to PCAC →
- 2026-05-03 DSIP / Emideltide: how it got to PCAC →
- 2026-05-03 Epitalon: how it got to PCAC →
- 2026-05-03 FDA's history of nominating bulk substances for compounding →
- 2026-05-03 GHK-Cu: how it got to PCAC →
- 2026-05-03 KPV: how it got to PCAC →
- 2026-05-03 Cathelicidin / LL-37: how it got to PCAC →
- 2026-05-03 Melanotan II: how it got to PCAC →
- 2026-05-03 MOTs-C: how it got to PCAC →
- 2026-05-03 PCAC July 23, 2026: Four peptides under review (preview) →
- 2026-05-03 PCAC July 24, 2026: Three peptides under review (preview) →
- 2026-05-03 PEG-MGF: how it got to PCAC →
- 2026-05-03 Peptides as drugs vs research chemicals: the legal distinction →
- 2026-05-03 Reading FDA briefing documents: a primer →
- 2026-05-03 Semax: how it got to PCAC →
- 2026-05-03 TB-500: how it got to PCAC →
- 2026-05-03 What happens when PCAC says yes / no / abstain →
- 2026-05-03 What is the PCAC? →